InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-42.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Lochner Daniel, Chief Financial Officer. Insider active across 3 companies, notably Oyster Point Pharma, Inc.. Cumulatively, 12 reports have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €241k. Activity tracked since 28 July 2021. The latest transaction was disclosed on 5 February 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
4,617 shares@ US$54.14100.0% of flowCommon StockSEC:0001415889-25-003350:0
Ideal exit: 2 Nov 2025 (T+270)
18,074 shares0Common StockSEC:0001415889-25-003227:0
938 shares@ US$11.701.9% of flowCommon StockSEC:0001209191-23-001073:0
3,258 shares@ US$11.206.9% of flowCommon StockSEC:0001209191-22-059938:0
19,500 shares0Common StockSEC:0001209191-22-002978:0
19,500 shares0Common StockSEC:0001209191-22-002978
8,590 shares@ US$11.5118.5% of flowCommon StockSEC:0001209191-21-062476:0
8,590 shares@ US$11.5116.9% of flowCommon StockSEC:0001209191-21-062476
7,500 shares@ US$11.5115.7% of flowCommon StockSEC:0001209191-21-054919:0
7,500 shares@ US$11.5114.3% of flowCommon StockSEC:0001209191-21-054919
7,500 shares@ US$11.5114.4% of flowCommon StockSEC:0001209191-21-048517
7,500 shares@ US$11.5115.8% of flowCommon StockSEC:0001209191-21-048517:0
12 of 12 declarations
About Lochner Daniel
Daniel Lochner is the Chief Financial Officer at Oyster Point Pharma, Inc., a biopharmaceutical company focused on developing treatments for eye diseases. He is responsible for the financial management of the company, including budgeting and financial reporting.
